20 articles
Comprehensive comparison of Stereo-seq, Visium HD, CosMx, and Xenium platforms reveals key performance differences for cancer research applications.
Path2Space uses deep learning to infer spatial gene expression from standard tissue slides, enabling low-cost breast cancer biomarker discovery at scale.
New 3-D spatial mapping reveals four distinct immune-evasion niches in osteosarcoma that explain why checkpoint therapies fail.
Researchers used advanced genetic analysis to find LGALS9 and SELL genes causally linked to aggressive brain tumors, revealing new treatment targets.
Spatial multi-omics reveals how specific fibroblasts create immunosuppressive environments that fuel colorectal cancer spread to the liver.
A Dana-Farber/Broad Institute study links glioblastoma transcriptional states to survival outcomes in patients receiving immune checkpoint blockade.
A landmark genomic analysis of 50,000 tumors maps cancer-driving mutations across tumor types, revealing critical patterns that could reshape precision oncology.
Researchers integrated brain protein and gene data to identify EGFR, SCFD1, and GMPPB as promising new targets for treating deadly brain cancer.
STAR-FACS technique enables researchers to isolate and study rare cancer cells with specific mutations, revealing how genetic changes drive tumor behavior.
New research reveals how chemical tags on RNA molecules drive cancer progression and could unlock targeted treatments.
Scientists discover that 3' UTRs of mRNAs actively guide protein folding during translation, controlling activity of key cancer and aging regulators.
A 13-modality molecular analysis of 173 AML patients reveals distinct subtypes, metabolic reprogramming, and a machine-learning-validated therapy target.
Cell publishes a tribute to Gregory J. Hannon, whose landmark work on RNAi and piRNA pathways reshaped cancer biology and gene regulation.
A comprehensive review reveals how combining genomics, proteomics, and metabolomics is uncovering new AML targets and improving patient outcomes.
Researchers found a rogue RNA molecule that fuels liver cancer by boosting protein synthesis, opening new treatment pathways.
A blood-based immune biomarker predicts which breast cancer patients will respond to checkpoint immunotherapy, validated across two independent cohorts.
A large genomic study finds mesenchymal glioblastoma responds better to immune checkpoint blockade, opening a path to smarter patient selection.
New ColonTrack model identifies early-stage colorectal cancer with 94% accuracy using three proteins from blood-based extracellular vesicles.
END-seq reveals ALT-positive cancer telomeres share canonical 5′ ATC termini with normal cells, but harbor uniquely abundant single-stranded DNA regions.
A 156-patient multimodal study reveals two distinct immune microenvironments in breast cancer brain metastases that predict survival and immunotherapy response.
